{"url_path":"/sec/vani/8-k/2026-07-07/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 Other Information","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-07","source_url":"https://www.sec.gov/Archives/edgar/data/1266806/0001753926-26-001144-index.html","accession_number":"0001753926-26-001144","cik":"0001266806","ticker":"VANI","issuer_name":"Vivani Medical, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1266806/0001753926-26-001144-index.html","primary_entity_key":"0001266806","primary_entity_name":"Vivani Medical, Inc."},"word_count":61,"has_tables":true,"body_markdown":"Item 8.01. Other Information\n\n \n\nOn July 7, 2026, Vivani issued a press release announcing the entry into an agreement with Novo Nordisk to evaluate NPM-139, its semaglutide drug implant that utilizes Vivani’s NanoPortal platform technology, which is under development for chronic weight management.\n\n \n\nA copy of the press release is filed as Exhibit 99.1 hereto and is incorporated by reference herein."}